CRISPR Assays for Disease Diagnosis: Progress to and Barriers Remaining for Clinical Applications.

Adv Sci (Weinh)

Center for Cellular and Molecular Diagnostics, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA, 70112, USA.

Published: July 2023

Numerous groups have employed the special properties of CRISPR/Cas systems to develop platforms that have broad potential applications for sensitive and specific detection of nucleic acid (NA) targets. However, few of these approaches have progressed to commercial or clinical applications. This review summarizes the properties of known CRISPR/Cas systems and their applications, challenges associated with the development of such assays, and opportunities to improve their performance or address unmet assay needs using nano-/micro-technology platforms. These include rapid and efficient sample preparation, integrated single-tube, amplification-free, quantifiable, multiplex, and non-NA assays. Finally, this review discusses the current outlook for such assays, including remaining barriers for clinical or point-of-care applications and their commercial development.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369298PMC
http://dx.doi.org/10.1002/advs.202301697DOI Listing

Publication Analysis

Top Keywords

clinical applications
8
properties crispr/cas
8
crispr/cas systems
8
applications
5
crispr assays
4
assays disease
4
disease diagnosis
4
diagnosis progress
4
progress barriers
4
barriers remaining
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!